Telomir-1 shows dose-dependent reversal of Wilson's disease symptoms in animal model

Telomir Pharmaceuticals, Inc.

Up to 4-5x reduction in episodic tremor events; normalization of swim and exploratory behavior.
Approximately 50% reduction in copper accumulation in dry liver tissue.
ALT, AST, bilirubin restored to normal levels, indicating protection of liver function.
Significant improvement in liver and kidney histopathology scores to near-normal.
IND submission planned by year-end; human clinical trials targeted for H1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.